Bull case
NervGen Pharma is attractive because its lead asset NVG-291 has shown compelling proof-of-concept in subacute and chronic cervical motor incomplete SCI, including 2.6x greater mean GRASSP Total Score improvement versus placebo, 3.7x greater grasping gains, durable post-treatment functional recovery, and no treatment-related serious adverse events. The company also appears financially and operationally de-risked after completing a $60M underwritten offering of 24M shares plus 24M warrants, which should fund the RESTORE Phase 3 program and may support future commercial buildout if exercised. Fundamentally, the investment case is strengthened by a rigorous ~150-patient registrational design, FDA alignment that one positive study may be sufficient, long-dated IP through at least 2037 for NVG-291 and beyond 2040 for NVG-300, and a large unmet SCI market with projected $150–300K per-course pricing and $2–4 billion peak annual U.S. revenue potential.